How Investors Are Reacting To Gilead Sciences (GILD) FDA Drug Approvals

Gilead Sciences recently secured multiple FDA decisions, including approval for the Bixlenvo HIV regimen, a label expansion for Trodelvy in first line metastatic triple negative breast cancer, and approval for Hepcludex for chronic hepatitis delta. The company is also preparing to share new data across HIV and antiviral programs at IDWeek 2026. These regulatory milestones arrive as Gilead Sciences absorbs acquired research costs that led to a reported US$3.24b loss over the twelve months to...